In Prospector

Similar Items

• FDA's drug and device review process : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Second Congress, second session, February 6, 1992
  by: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Oversight and Investigations.
  Published: (1992)
• A delicate balance FDA and the reform of the medical device approval process : hearing before the Special Committee on Aging, United States Senate, One Hundred Twelfth Congress, first session, Washington, DC, April 13, 2011
  by: United States. Congress. Senate. Special Committee on Aging.
  Published: (2011)
• Implementing the 21st Century Cures Act : an update from FDA and NIH : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Fifteenth Congress, first session, November 30, 2017
  by: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health,
  Published: (2019)
• Regulating innovation : FDA's medical device approval process : hearing before the Subcommittee on Investigations and Oversight of the Committee on Science, Space, and Technology, U.S. House of Representatives, One Hundred Third Congress, first session, September 17, 1993
  by: United States. Congress. House. Committee on Science, Space, and Technology. Subcommittee on Investigations and Oversight.
  Published: (1993)
• FDA user fees 2012 : how innovation helps patients and jobs : hearing before the Subcommittee on Health of the Committee on Energy and Commerce, House of Representatives, One Hundred Twelfth Congress, second session, April 18, 2012
  by: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health,
  Published: (2013)